Vytrus Biotech H1 FY26 net profit climbs 73% to EUR 2.5 million

Reuters2026/07/20 06:39

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vytrus Biotech H1 2026 net sales rose 37% to EUR 6 million.
EBITDA climbed 67% to EUR 3.48 million; EBITDA margin widened 10.3 percentage points to 57.9%.
Net profit increased 73% to EUR 2.5 million; operating cash flow rose 91% to EUR 2.75 million.
EU net sales grew 49% while U.S. net sales fell 14%; trailing 12-month net sales reached EUR 10 million.
Launched Toleroxyl on July 1, the first product from its recombinant-protein platform, to broaden beyond plant stem cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vytrus Biotech SA published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vytrus Biotech H1 FY26 net profit climbs 73% to EUR 2.5 million

You may also like

Crypto prices